Voluntary nationwide recall: Zenzedi (Azurity - January)

Feb. 2024Pharmacy Updates
Azurity Pharmaceuticals Inc. is recalling one lot of Zenzedi tablets, USP 30 mg. Zenzedi is used for the treatment of narcolepsy (a sleep disorder) and attention deficit hyperactivity disorder (ADHD).

This drug is being recalled because tablets of Carbinoxamine Maleate, an antihistamine drug, were found in a Zenzedi bottle during pharmacy dispensing. Patients who take carbinoxamine instead of Zenzedi® will experience undertreatment of their symptoms, which may result in functional impairment and an increased risk of accidents or injury. Administration of Carbinoxamine may cause adverse events which include, but are not limited to, drowsiness, sleepiness, central nervous system (CNS) depression, increased eye pressure, enlarged prostate urinary obstruction, and thyroid disorder.

As of the date of Azurity’s recall announcement, Jan. 24, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.

If you have an affected lot of Zenzedi, you should stop using the item and return it to the place of purchase.

To learn more about this recall, you can take one or more of the steps below.
  • Talk to your doctor or pharmacist.
  • Call Inmar Intelligent at 1-877-804-2069. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.


Recent Announcements

UPMC Dental Advantage celebrates 15-years of growth

From pilot program to now serving all product lines
Jan. 2026What's New

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Jan. 2026Important Notices

Important: Expedited appeals fax requirement

Please remember that you must adhere to the designated process for submitting expedited appeals to have them processed in a timely manner. Follow these guidelines to help you successfully submit expedited appeals:
Jan. 2026Important Notices